Authors : Aishwar J. P.; Madhavan S.; Vijaykeasavan K.; Mohammed Vahith S.; Asarajarathinam A.; Masco M.; Suriyakala P.; Kalaivani R.; Dr. Nepolean R.

Volume/Issue : Volume 11 - 2026, Issue 1 - January

Google Scholar : https://tinyurl.com/34vhx4ue

Scribd : https://tinyurl.com/496b6v2b

DOI : https://doi.org/10.38124/ijisrt/26jan268

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : The field of cardio-oncology is a service that is new and which integrates various disciplines to assist individuals with cardiac issues that may occur during the course of cancer development or during the administration of treatment. New cancer therapies have increased the chances of individuals living longer, though most of these therapies may result in heart disorders, such as cardiomyopathy, heart failure, arrhythmias, high blood pressure, and thromboembolic incidents. These issues can make both cancer outcomes and heart health worse. Cardio-oncology is the study of the hearts and blood vessels of people with cancer. Before treatment, it includes a full cardiovascular risk assessment. During treatment, it includes constant monitoring, quick detection of cardiotoxicity, and long-term cardiac care for cancer survivors. People who work in this field try to find a way to treat cancer while also keeping the heart safe. Some are oncologists, cardiologists, pharmacists, and other health care workers. Imaging tests are some of the most essential strategies, as they assist doctors in determining what is wrong, heart-protecting drugs as well as personalized treatment plans that are designed on a case-by- case basis. Pharmacists can help a lot, monitors of your medications, and ensures that they do not interact with other drugs and maximizes on therapy. The rules are increasing, yet much of the evidence remains grounded on what individuals concur on. This implies that we should have more good research that is forward looking. Cardio-oncology is quite crucial in ensuring that individuals with cancer live longer, safer, and better lives.

Keywords : Cardio-Oncology, Cancer Therapy, Cardiotoxicity, Cardiovascular Complications, Chemotherapy, Targeted Therapy, Cancer Survivorship, Risk Stratification, Biomarkers, Cardiac Imaging, Pharmacologic Prevention, Heart Failure, Anthracyclines, Multidisciplinary Care, Personalized Medicine, Pharmacists’ Role, Clinical Guidelines, Cardiovascular Monitoring, Cardioprotection, Long-Term Outcomes.

References :

1. Herrmann, Joerg et al. “Evaluation and management of patients with heart disease and cancer: cardio-oncology.” Mayo Clinic proceedings vol. 89,9 (2014): 1287-306 . https://doi.org/10.1016/j.mayocp.2014.05.013
2. Domercant, Jean et al. “Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management.” The Ochsner journal 16 3 (2016): 250-6 .
3. M.S. Andres;J. Pan;A.R. Lyon;. (2021). What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist? . Clinical Oncology, (), https://doi.org/10.1016/j.clon.2021.03.012
4. M Andres, T M Murphy, N Poku, S Nazir, S Ramalingam, V Chambers, S D Rosen, A R Lyon, Cardio-Oncology: a medical specialty in constant growth and evolution. the 10-year experience of the first cardio-oncology service in the United Kingdom, European Heart Journal, Volume 43, Issue Supplement_2, October 2022, ehac544.2564, https://doi.org/10.1093/eurheartj/ehac544.2564
5. Pan, Jiliu et al. “Cardio-oncology: rationale, aims and future directions.” Current Opinion in Supportive and Palliative Care 15 (2021): 134 - 140. https://doi.org/10.1097/SPC.0000000000000544
6. Florido, Roberta et al. “Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study.” Journal of the American College of Cardiology 80 1 (2022): 22-32 . https://doi.org/10.1016/j.jacc.2022.04.042
7. Alshahrani, Ali A et al. “Cardiovascular diseases in patients with cancer: A comprehensive review of epidemiological trends, cardiac complications, and prognostic implications.” Chinese Medical Journal 138 (2024): 143 - 154. https://doi.org/10.1097/CM9.0000000000003419
8. Muhandiramge, Jaidyn et al. “Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology.” Current oncology reports vol. 24,11 (2022): 1579-1592. https://doi.org/10.1007/s11912-022-01309-w
9. Kamaraju, Sailaja et al. “Interactions between cardiology and oncology drugs in precision cardio-oncology.” Clinical science 135 11 (2021): 1333-1351 . https://doi.org/10.1042/CS20200309
10. Barros-Gomes, Sergio et al. “Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic.” Cardio-oncology (London, England) vol. 2,1 5. 19 Apr. 2016, https://doi.org/10.1186/s40959-016-0014-2
11. Nagy, András et al. “A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms.” Cardiovascular drugs and therapy vol. 39,5 (2025): 1185-1199. https://doi.org/10.1007/s10557-024-07574-0
12. Narezkina, Anna et al. “Molecular mechanisms of anthracycline cardiovascular toxicity.” Clinical science 135 10 (2021): 1311-1332 . https://doi.org/10.1042/CS20200301
13. McGowan, John V et al. “Anthracycline Chemotherapy and Cardiotoxicity.” Cardiovascular drugs and therapy vol. 31,1 (2017): 63-75. https://doi.org/10.1007/s10557-016-6711-0
14. Abdul-Rahman, Toufik et al. “Chemotherapy Induced Cardiotoxicity: A State of the Art Review on General Mechanisms, Prevention, Treatment and Recent Advances in Novel Therapeutics.” Current problems in cardiology (2023): 101591 . https://doi.org/10.1016/j.cpcardiol.2023.101591
15. Al Khafaji, Adnan Taan et al. “Managing Doxorubicin Cardiotoxicity: Insights Into Molecular Mechanisms and Protective Strategies.” Journal of Biochemical and Molecular Toxicology 39 (2025): n. pag. https://doi.org/10.1002/jbt.70155
16. López-Sendón, José et al. “Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry.” European heart journal vol. 41,18 (2020): 1720-1729. https://doi.org/10.1093/eurheartj/ehaa006
17. Menna, Pierantonio et al. “Cardiotoxicity of antitumor drugs.” Chemical research in toxicology 21 5 (2008): 978-89 . https://doi.org/10.1021/tx800002r
18. Senkus, Elżbieta and Jacek Jassem. “Cardiovascular effects of systemic cancer treatment.” Cancer treatment reviews 37 4 (2011): 300-11 . https://doi.org/10.1016/j.ctrv.2010.11.001
19. Morelli, Marco Bruno et al. “Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.” Frontiers in cardiovascular medicine vol. 9 847012. 15 Apr. 2022, https://doi.org/10.3389/fcvm.2022.847012
20. Adão, Rui et al. “Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies.” Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 32 5 (2013): 395-409 . https://doi.org/10.1016/j.repc.2012.11.002
21. Qiu, Shuo et al. “Risk Factors for Anthracycline-Induced Cardiotoxicity.” Frontiers in cardiovascular medicine vol. 8 736854. 29 Sep. 2021, https://doi.org/10.3389/fcvm.2021.736854
22. Polonsky, Tamar S. and Jeanne M. DeCara. “Risk factors for chemotherapy-related cardiac toxicity.” Current Opinion in Cardiology 34 (2019): 283–288. https://doi.org/10.1097/HCO.0000000000000619
23. Bhave, Manali A. et al. “An update on the risk prediction and prevention of anticancer therapy-induced cardiotoxicity.” Current Opinion in Oncology 26 (2014): 590–599. https://doi.org/10.1097/CCO.0000000000000132
24. Zhang, X.; Sun, Y.; Zhang, Y.; Fang, F.; Liu, J.; Xia, Y.; Liu, Y. Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity. J. Cardiovasc. Dev. Dis. 2022, 9, 372. https://doi.org/10.3390/jcdd9110372
25. Attanasio, U.; Di Sarro, E.; Tricarico, L.; Di Lisi, D.; Armentaro, G.; Miceli, S.; Fioretti, F.; Deidda, M.; Correale, M.; Novo, G.; et al. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond. Biomolecules 2024, 14, 199. https://doi.org/10.3390/biom14020199
26. Semeraro, G.C.; Cipolla, C.M.; Cardinale, D.M. Role of Cardiac Biomarkers in Cancer Patients. Cancers 2021, 13, 5426. https://doi.org/10.3390/cancers13215426
27. Ananthan, Kajaluxy, and Alexander R Lyon. “The Role of Biomarkers in Cardio-Oncology.” Journal of cardiovascular translational research vol. 13,3 (2020): 431-450. https://doi.org/10.1007/s12265-020-10042-3
28. Travers, Simon et al. “Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments.” Archives of cardiovascular diseases (2025): n. pag. https://doi.org/10.1016/j.acvd.2024.12.012
29. Wadden, Elena et al. “Evolving Cardioprotective Strategies in Cardio-Oncology: A Narrative Review.” Current Cardiology Reports 27 (2025): n. pag. https://doi.org/10.1007/s11886-025-02283-y
30. Sadigova, T. “Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection.” American Journal of Biomedical and Life Sciences (2024): n. pag. https://doi.org/10.11648/j.ajbls.20241206.11
31. Padegimas, Allison et al. “Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity.” Trends in cardiovascular medicine vol. 30,1 (2020): 22-28. https://doi.org/10.1016/j.tcm.2019.01.006
32. Dent, Susan et al. “Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment-Related Cardiovascular Toxicity.” American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 40 (2020): 1-15 . https://doi.org/10.1200/EDBK_286019
33. Quagliariello, Vincenzo et al. “Healthcare Management in Cardio-Oncology, Clinical Strategies and Future Perspectives: A Narrative Review.” Healthcare 13 (2025): n. pag. https://doi.org/10.3390/healthcare13202599
34. Curigliano, G et al. “Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.” Annals of oncology : official journal of the European Society for Medical Oncology vol. 31,2 (2020): 171-190. https://doi.org/10.1016/j.annonc.2019.10.023
35. Parent, Sarah et al. “The Cardio-oncology Program: A Multidisciplinary Approach to the Care of Cancer Patients With Cardiovascular Disease.” The Canadian journal of cardiology 32 7 (2016): 847-51 . https://doi.org/10.1016/j.cjca.2016.04.014
36. Yaseen, Israa Fadhil, and Hasan Ali Farhan. “Cardiovascular drug interventions in the cardio-oncology clinic by a cardiology pharmacist: ICOP-Pharm study.” Frontiers in cardiovascular medicine vol. 9 972455. 29 Sep. 2022, https://doi.org/10.3389/fcvm.2022.972455
37. Merali, Ali-Reza et al. “Exploration of current pharmacy practice in cardio-oncology: Experiences & perspectives.” Journal of Oncology Pharmacy Practice 29 (2022): 1844 - 1852. https://doi.org/10.1177/10781552221145667
38. Shibutani, Yuma and Makoto Hiraide. “Questionnaire survey on efforts and challenges in cardio-oncology among pharmacists: A cross-sectional survey of the pharmacists of the Japanese Onco-Cardiology Society.” Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2025): . https://doi.org/10.1177/10781552251349135
39. Rassaf, Tienush, and Matthias Totzeck. “Modern concepts in cardio-oncology.” Journal of thoracic disease vol. 10,Suppl 35 (2018): S4386-S4390. https://doi.org/10.21037/jtd.2018.11.110
40. Khouri, Michel G et al. “Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.” Future cardiology vol. 11,4 (2015): 471-84. https://doi.org/10.2217/fca.15.16
41. Campia, Umberto et al. “Cardio-Oncology: Vascular and Metabolic Perspectives A Scientific Statement From the American Heart Association.” Circulation 139 (2019): e579–e602. https://doi.org/10.1161/CIR.0000000000000641
42. Beyer, Andreas M et al. “Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs.” American journal of physiology. Heart and circulatory physiology vol. 317,1 (2019): H164-H167. https://doi.org/10.1152/ajpheart.00277.2019
43. Kreidieh, Firas and Jennifer McQuade. “Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA).” American Heart Hournal Plus: Cardiology Research and Practice 40 (2024): n. pag. https://doi.org/10.1016/j.ahjo.2024.100374
44. Gent, David G, and Dobson Rebecca. “The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus.” European cardiology vol. 18 e16. 21 Apr. 2023, https://doi.org/10.15420/ecr.2022.63
45. Teske, Arco J.. “The ESC cardio-oncology 2022 guidelines; the ball is in our court.” European heart journal. Cardiovascular Imaging (2022): n. pag. https://doi.org/10.1093/ehjci/jeac219
46. Leong, Darryl P. and Daniel J. Lenihan. “Clinical Practice Guidelines in Cardio-Oncology.” Heart failure clinics 18 3 (2022): 489-501 . https://doi.org/10.1016/j.hfc.2022.02.002
47. Viñas-Mendieta, Adriana E et al. “Cardio-oncology: chances and challenges.” Basic Research in Cardiology 120 (2024): 3 - 9. https://doi.org/10.1007/s00395-024-01080-y
48. Lenihan, Daniel J. et al. “Proceedings From the Global Cardio-Oncology Summit.” JACC: CardioOncology 1 (2019): 256 - 272. https://doi.org/10.1016/j.jaccao.2019.11.007
49. Pan, Jiliu et al. “Cardio-oncology: rationale, aims and future directions.” Current Opinion in Supportive and Palliative Care 15 (2021): 134 - 140. https://doi.org/10.1097/SPC.0000000000000544